![](/img/cover-not-exists.png)
Optimal timing and duration of the use of an aromatase inhibitor (Al) in the adjuvant treatment of postmenopausal hormone receptor-positive (HR+) breast cancer (BC)
J. CuzickVolume:
6
Year:
2008
Language:
english
DOI:
10.1016/s1359-6349(08)70562-7
File:
PDF, 56 KB
english, 2008